SEC Form 4 · accession 0001209191-17-035824
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick Fourteau
Director
Period of report
May 26, 2017
Accepted (ET)
May 26, 2017 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 26, 2017 | M | 10,000 | $3.63 | A | 59,682 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.63 | May 26, 2017 | M | 10,000 | D | — | May 14, 2023 | Common Stock | 10,000 | 50,000 | D |
Explanation of responses
- F1The option was fully vested as of May 14, 2016.